Industry Specific Issues

CBA Settlement of Disputed Claims for Software R&D Activities

March 18th, 2019

CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute regarding the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]

Read More

Australia’s Attractiveness for Clinical Trials

March 6th, 2019

To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]

Read More

New AusIndustry Guidance Released on Software Development

February 21st, 2019

AusIndustry have released two additional guidance documents particularly relevant to claimants conducting software development R&D activities: Software activities and the R&D Tax Incentive; Guide to Common Errors; This guidance has been released following earlier material from AusIndustry indicating concerns over inappropriate claims for Software Activities, and reports in the media of large software development R&D claims being found to be ineligible during review. The general principles within this new guidance remains consistent, in that claimants must demonstrate how their software is […]

Read More

Senate Economics Committee Review Into Proposed R&D Tax Incentive Changes

January 31st, 2019

The Senate Economics Legislation Committee conducted a public hearing in Melbourne on 30 January which heard submissions from various stakeholders including: Cochlear Ltd; Brickworks Ltd; CSL; Dulux Group; The AFR has reported that representatives from these groups have consistently argued that continual change to R&D Tax Incentive introduces uncertainty and reduces Australia’s relative attractiveness as an investment location. In fact, R&D spending in Australia has fallen by over $2 billion since 2013-14. The proposed intensity threshold for companies with annual turnover […]

Read More

Email this job

[recaptcha]